Table 2.
Percent of Females with Zika Virus Viremia at 7 Days Post Infection.
| Treatment | Replicate 1 | Replicate 2 | Replicate 3 | Average |
|---|---|---|---|---|
| Intravaginal Inoculation Treatment | ||||
| One (+EF/+SP) | 100% (5/5) | 80% (4/5) | 60% (3/5) | 80% (12/15) |
| Two (+EF/−SP) | 40% (2/5) | 40% (2/5) | 100% (5/5) | 60% (9/15) |
| Three (−EF/+SP) | 100% (5/5) | 20% (1/5) | 0% (0/5) | 40% (6/15) |
| Four (−EF/−SP; Spike) | 80% (4/5); Progesterone | 80% (4/5); Non-progesterone | NA | 80% (8/10) |
| Five (MEM Spike) | 20% (1/5); Progesterone | 0% (0/5); Non-Progesterone | NA | 10% (1/10) |
| Six (−EF/−SP) | 0% (0/5) | NA | NA | 0% (0/0) |
| Subcutaneous Inoculation Treatment | ||||
| One (+EF/+SP) | 100% (3/3) | 66.66% (2/3) | 100% (3/3) | 88.88% (8/9) |
| Two (+EF/−SP) | 100% (3/3) | 100% (3/3) | 100% (3/3) | 100% (9/9) |
| Three (−EF/+SP) | 100% (3/3) | 66.66% (2/3) | 66.66% (2/3) | 77.77% (7/9) |
| Four (−EF/−SP; Spike) | 100% (3/3); Progesterone | NA | NA | 100% (3/3) |
| Five (MEM Spike) | 100% (3/3); Progesterone | 100% (2/2); Non-Progesterone | NA | 100% (5/5) |
| Six (−EF/−SP) | 0% (0/3) | NA | NA | 0% (0/3) |
Average percent of females with ZIKV RNA detected in peripheral whole blood at 7 days post intra-vaginal and subcutaneous inoculation. EF = epididymal flush; SP = seminal plasma; + = Zika virus infected; − = Sham; MEM = Minimal Essential Media; NA = not applicable.